Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.55 |
| ▸ | NOS2 | P35228 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | CCND1 | P24385 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617396 | 0.87 | MAPK14 (0.61) | MAPK14NOS2NOS1MAPK8MAPK9 | |
| SCHEMBL1617454 | 0.81 | MAPK14 (0.73) | MAPK14 | |
| SCHEMBL4409259 | 0.81 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL4409254 | 0.81 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL13593860 | 0.80 | USP2 (0.44) | MAPK14NOS2NOS1MAPK8MAPK9 | |
| SCHEMBL1617118 | 0.79 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL12715597 | 0.78 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL15757225 | 0.77 | NUDT1 (0.66) | NOS2NOS1MAPK8MAPK9MAPK10 | |
| SCHEMBL1617211 | 0.74 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL1616706 | 0.74 | MAPK14 (0.65) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| EP-1848714-B1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | LIMK1, LIMK2, MAPK1 | MAPK14 83/4885NOS2 1798/4885NOS1 1238/4885 |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | LIMK1, LIMK2, MAPK1 | MAPK14 83/4885NOS2 1798/4885NOS1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.